- The key vendors in the multiple sclerosis market in the US 2015-2019 are Bayer AG, Biogen, Merck Serono, Novartis AG, and Teva Pharmaceutical Industries Ltd.
London, 1 July 2015: Technavio, an independent tech-focused global research firm, has announced the publication of its market research report on the multiple sclerosis market in the US 2015-2019. Strategic alliances formed between different companies to lower production costs is a significant trend observed in this market. Alliances between the various companies help to reduce manufacturing costs, gain access to target markets, and share resources for the fast and efficient development of drugs. The multiple sclerosis market in the US is expected to grow at a CAGR of 3.8% during the forecast period of 2014-2019.
The introduction of new drugs that treat multiple sclerosis is expected to facilitate growth in this market. Recent advances made in the field of healthcare have resulted in the introduction of innovative drugs in the product pipeline, which help to cure and control multiple sclerosis. Also, the US government’s initiative to financially assist patients who are suffering from multiple sclerosis will aid in the growth of this market.
“The US FDA has approved certain disease-modifying drugs for treating various forms of multiple sclerosis. These drugs interact with the immune system to reduce the number of relapses,” says Faisal Ghaus, Vice President of Technavio Research.
“Tysabri by Biogen, Gilenya by Novartis, and Betaseron by Bayer are some of the disease-modifying drugs indicated for the treatment of the disease; these drugs will be launched during the forecast period.”
To define the market conditions in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges, and trends featuring data on product segmentations, vendor shares, growth rate by revenue, and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
